News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Lancet Neurology Study: Promising Lou Gehrig’s Disease Drug Fails Trial
November 1, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - An acne drug that had shown early promise in treating the degenerative nerve condition known as Lou Gehrig's disease actually worsens it, a study in Lancet Neurology said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
MORE ON THIS TOPIC
Obesity
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
October 1, 2026
·
2 min read
·
Heather McKenzie
FDA
US government launches AI-driven programs to overhaul clinical trials
October 1, 2026
·
4 min read
·
Gabrielle Masson
Insights
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
October 1, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Obesity
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
September 30, 2026
·
3 min read
·
Heather McKenzie
